Clinical and laboratory features of rheumatoid arthritis in men depending on testosterone levels

BACKGROUND: It has been suggested that the presence of chronic immunoinflammatory rheumatic disease (CIRD) may be a factor that increases the likelihood of developing hypogonadism syndrome, and conversely, the presence of uncompensated testosterone deficiency may predispose to a greater risk of developing or more severe course of ICRD.

AIM: To study the incidence of hypogonadism in men with rheumatoid arthritis (RA) and evaluate its impact on the course of RA and concomitant diseases.

MATERIALS AND METHODS: A one-time continuous study included 170 men with RA who were undergoing inpatient treatment at the Federal State Budgetary Institution NIIR named after. V.A. Nasonova. Patients were assessed for total testosterone levels and subsequently divided into subgroups with normal (>12 nmol/l) and reduced levels. An intergroup comparison was carried out on the main indicators used in clinical rheumatological practice to assess the stage, activity and other medical and demographic characteristics of RA, as well as the state of purine and carbohydrate metabolism. A correlation analysis was performed between the level of total testosterone and some clinical and laboratory parameters.

RESULTS: The frequency of detected testosterone deficiency in the study group was 24.1%. Significant correlations were noted between the level of total testosterone and body mass index (r=-0.29), the level of blood uric acid (r=-0.19) and C-reactive protein (r=-0.18). Patients with hypogonadism compared to the group with normal testosterone levels were characterized by higher body mass index (29.3±5.6 vs 26.3±4.0 kg/m2; p<0.001), glucose levels (6.95±7 .85 mmol/l vs 5.42±1.13 mmol/l; p=0.034) and uric acid (354.6±110.7 vs 317.5±84.8 µmol/l; p=0.03) blood. In addition, patients with hypogonadism were more likely to suffer from obesity (41.6% vs 15.7%; p=0.001) and diabetes mellitus (21.6% vs 10.2%; p=0.075) without a statistically significant difference, and also had higher ESR (46.5±42.2 vs 31.0±30.9 mm/h; p=0.012). A more frequent occurrence of anemia was noted in hypogonadism (32.4% vs 16.7%; p=0.041).

CONCLUSION: Testosterone levels and the presence of hypogonadism were not associated with the stage and activity of RA, however, testosterone deficiency was accompanied by a more frequent development of overweight and obesity, and a deterioration in purine and carbohydrate metabolism.

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. doi: https://doi.org/10.1016/S0140-6736(16)30173-8

2. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99. doi: https://doi.org/10.1136/annrheumdis-2019-216655

3. Gordeev AV, Matyanova EV, Olyunin YuA, et al. Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look. Modern Rheumatology Journal. 2022;16(2):13-20. (In Russ.) doi: https://doi.org/10.14412/1996-7012-2022-2-13-20

4. Dedov II, Mokrysheva NG, Melnichenko GA, et al. Draft of Russian clinical practice guidelines «Male hypogonadism». Obesity and metabolism. 2021;18(4):496-507 doi: https://doi.org/10.14341/omet12817

5. Panevin TS, Rozhivanov RV, Nasonov EL. Hypogonadism syndrome in men with inflammatory joint diseases: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(5):429–433 (In Russ.) doi: https://doi.org/10.26442/00403660.2023.05.202199

6. Baillargeon J, Al Snih S, Raji MA, et al. Hypogonadism and the risk of rheumatic autoimmune disease. Clin Rheumatol. 2016;35(12):2983-2987. doi: https://doi.org/10.1007/s10067-016-3330-x

7. Yang DD, Krasnova A, Nead KT, et al. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018;29(2):386-391. doi: https://doi.org/10.1093/annonc/mdx744

8. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313-3318. doi: https://doi.org/10.1210/jc.2003-031069

9. Прокаева Т.Б. Ревматоидный артрит у мужчин: автореф. дис. ... канд. мед. наук / Т. Б. Прокаева. — М., 1991. — 25 с.

10. Tengstrand B, Carlström K, Hafström I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford). 2002;41(3):285-289. doi: https://doi.org/10.1093/rheumatology/41.3.285

11. Kondrashov AA, Shostak NA. Composition of the body in male patients with rheumatoid arthritis with account of androgenic status. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):700–707 doi: https://doi.org/10.47360/1995-4484-2021-700-707

12. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int. J. Androl. 2009;32(6):587–98. doi: https://doi.org/10.1111/j.1365-2605.2008.00951.x

13. Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. Journal of Endocrinological Investigation. 2016;39(9):967–81. doi: https://doi.org/10.1007/s40618-016-0480-2

14. Castagnetta LA, Carruba G, Granata OM, et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 2003;30(12):2597-2605

15. Cutolo M, Sulli A, Straub RH. Estrogen metabolism and autoimmunity. Autoimmun Rev. 2012;11(6-7):A460-A464. doi: https://doi.org/10.1016/j.autrev.2011.11.014